Next Article in Journal
Protein Distribution and Muscle-Related Outcomes: Does the Evidence Support the Concept?
Next Article in Special Issue
The Effect of Natural Antioxidants in the Development of Metabolic Syndrome: Focus on Bergamot Polyphenolic Fraction
Previous Article in Journal
Influence of the Mediterranean Diet on 25-Hydroxyvitamin D Levels in Adults
Previous Article in Special Issue
Association between Three Low-Carbohydrate Diet Scores and Lipid Metabolism among Chinese Adults
Review

Naturally Occurring PCSK9 Inhibitors

1
Department of Medicine and Surgery-Unit of Neurosciences, University of Parma, 43125 Parma, Italy
2
Dipartimento di Scienze degli Alimenti e del Farmaco, Università di Parma, 43124 Parma, Italy
3
Dipartimento di Scienze del Farmaco, Università degli Studi di Padova, 35121 Padova, Italy
4
Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, 20122 Milan, Italy
*
Author to whom correspondence should be addressed.
Nutrients 2020, 12(5), 1440; https://doi.org/10.3390/nu12051440
Received: 20 April 2020 / Revised: 12 May 2020 / Accepted: 13 May 2020 / Published: 16 May 2020
(This article belongs to the Special Issue Diets, Foods and Food Components Effect on Dyslipidemia)
Genetic, epidemiological and pharmacological data have led to the conclusion that antagonizing or inhibiting Proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces cardiovascular events. This clinical outcome is mainly related to the pivotal role of PCSK9 in controlling low-density lipoprotein (LDL) cholesterol levels. The absence of oral and affordable anti-PCSK9 medications has limited the beneficial effects of this new therapeutic option. A possible breakthrough in this field may come from the discovery of new naturally occurring PCSK9 inhibitors as a starting point for the development of oral, small molecules, to be used in combination with statins in order to increase the percentage of patients reaching their LDL-cholesterol target levels. In the present review, we have summarized the current knowledge on natural compounds or extracts that have shown an inhibitory effect on PCSK9, either in experimental or clinical settings. When available, the pharmacodynamic and pharmacokinetic profiles of the listed compounds are described. View Full-Text
Keywords: nutraceuticals; PCSK9; SREBP; HNF1α; berberine; cholesterol nutraceuticals; PCSK9; SREBP; HNF1α; berberine; cholesterol
Show Figures

Graphical abstract

MDPI and ACS Style

Adorni, M.P.; Zimetti, F.; Lupo, M.G.; Ruscica, M.; Ferri, N. Naturally Occurring PCSK9 Inhibitors. Nutrients 2020, 12, 1440. https://doi.org/10.3390/nu12051440

AMA Style

Adorni MP, Zimetti F, Lupo MG, Ruscica M, Ferri N. Naturally Occurring PCSK9 Inhibitors. Nutrients. 2020; 12(5):1440. https://doi.org/10.3390/nu12051440

Chicago/Turabian Style

Adorni, Maria P., Francesca Zimetti, Maria G. Lupo, Massimiliano Ruscica, and Nicola Ferri. 2020. "Naturally Occurring PCSK9 Inhibitors" Nutrients 12, no. 5: 1440. https://doi.org/10.3390/nu12051440

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop